Clinical Validation and Treatment Plan Evaluation Based on Autodelineation of the Clinical Target Volume for Prostate Cancer Radiotherapy

被引:6
|
作者
Shen, Jing [1 ]
Tao, Yinjie [1 ]
Guan, Hui [1 ]
Zhen, Hongnan [1 ]
He, Lei [1 ]
Dong, Tingting [1 ]
Wang, Shaobin [2 ]
Chen, Yu [2 ]
Chen, Qi [2 ]
Liu, Zhikai [1 ,3 ]
Zhang, Fuquan [1 ]
机构
[1] Peking Union Med Coll Hosp, Dept Radiat Oncol, Beijing, Peoples R China
[2] MedMind Technol Co, Radiotherapy Tech Dev Dept, Beijing, Peoples R China
[3] Chinese Acad Med Sci & Peking Union Med Coll, 1 Shuaifuyuan Wangfujing, Beijing 100730, Peoples R China
关键词
prostate cancer radiotherapy; convolutional neural networks; clinical target volume; deep learning; DVH dosimetric index; RADIATION-THERAPY; SEGMENTATION; DELINEATION; ORGANS; RISK; CT;
D O I
10.1177/15330338231164883
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PurposeClinical target volumes (CTVs) and organs at risk (OARs) could be autocontoured to save workload. This study aimed to assess a convolutional neural network for automatic and accurate CTV and OARs in prostate cancer, while comparing possible treatment plans based on autocontouring CTV to clinical treatment plans. MethodsComputer tomography (CT) scans of 217 patients with locally advanced prostate cancer treated at our hospital were retrospectively collected and analyzed from January 2013 to January 2019. A deep learning-based method, CUNet, was used to delineate CTV and OARs. A training set of 195 CT scans and a test set of 28 CT scans were randomly chosen from the dataset. The mean Dice similarity coefficient (DSC), 95th percentile Hausdorff distance (95HD), and subjective evaluation were used to evaluate the performance of this strategy. Predetermined evaluation criteria were used to grade treatment plans, and percentage errors for clinical doses to the planned target volume (PTV) and OARs were calculated. ResultsThe mean DSC and 95HD values of the defined CTVs were (0.84 +/- 0.05) and (5.04 +/- 2.15) mm, respectively. The average delineation time was < 15 s for each patient's CT scan. The overall positive rates for clinicians A and B were 53.15% versus 46.85%, and 54.05% versus 45.95%, respectively (P > .05) when CTV outlines from CUNet were blindly chosen and compared with the ground truth (GT). Furthermore, 8 test patients were randomly chosen to design the predicted plan based on the autocontouring CTVs and OARs, demonstrating acceptable agreement with the clinical plan: average absolute dose differences in mean value of D2, D50, D98, Dmax, and Dmean for PTV were within 0.74%, and average absolute volume differences in mean value of V45 and V50 for OARs were within 3.4%. ConclusionOur results revealed that the CTVs and OARs for prostate cancer defined by CUNet were close to the GT. CUNet could halve the time spent by radiation oncologists in contouring, demonstrating the potential of the novel autocontouring method.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Clinical to planning target volume margins in prostate cancer radiotherapy
    Ramiandrisoa, F.
    Duverge, L.
    Castelli, J.
    Nguyen, T. D.
    Servagi-Vernat, S.
    de Crevoisier, R.
    CANCER RADIOTHERAPIE, 2016, 20 (6-7): : 629 - 639
  • [2] Treatment of prostate cancer with radiotherapy: Should the entire seminal vesicles be included in the clinical target volume?
    Kestin, LL
    Goldstein, NS
    Vicini, FA
    Yan, D
    Korman, HJ
    Martinez, AA
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2002, 54 (03): : 686 - 697
  • [3] The clinical relevance of target volume variability for prostate radiotherapy
    Livsey, J
    Mott, J
    Wylie, J
    Khoo, V
    Swindell, R
    Cowan, R
    Logue, J
    RADIOTHERAPY AND ONCOLOGY, 2003, 68 : S118 - S118
  • [4] DEFINING THE CLINICAL TARGET VOLUME FOR BLADDER CANCER RADIOTHERAPY TREATMENT PLANNING
    Jenkins, Peter
    Anjarwalla, Salim
    Gilbert, Hugh
    Kinder, Richard
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (05): : 1379 - 1384
  • [5] Clinical Assessment of the Planning Target Volume Margins for Stereotactic Body Radiotherapy of Prostate Cancer
    Cao, M.
    Qiao-Guan, G.
    Zhouhuizi, S.
    Steinberg, M. L.
    Nickols, N. G.
    Kupelian, P. A.
    King, C. R.
    Kishan, A. U.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E758 - E759
  • [6] Clinical Validation of ClearCheck, a Tool for Radiotherapy Plan Quality Evaluation
    Forbang, R. Teboh
    Ndlovu, A.
    MEDICAL PHYSICS, 2018, 45 (06) : E297 - E297
  • [7] Clinical Assessment of Prostate Displacement and Planning Target Volume Margins for Stereotactic Body Radiotherapy of Prostate Cancer
    Levin-Epstein, Rebecca
    Qiao-Guan, George
    Juarez, Jesus E.
    Shen, Zhouhuizi
    Steinberg, Michael L.
    Ruan, Dan
    Valle, Luca
    Nickols, Nicholas G.
    Kupelian, Patrick A.
    King, Christopher R.
    Cao, Minsong
    Kishan, Amar U.
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [8] Variability of radiotherapy volume delineation: PSMA PET/MRI and MRI based clinical target volume and lymph node target volume for high-risk prostate cancer
    Lin-Lin Liu
    Lei-Lei Zhu
    Zhen-Guo Lu
    Jun-Die Sun
    Jun Zhao
    Hai-Feng Wang
    Zuo-Lin Xiang
    Cancer Imaging, 23
  • [9] Variability of radiotherapy volume delineation: PSMA PET/MRI and MRI based clinical target volume and lymph node target volume for high-risk prostate cancer
    Liu, Lin-Lin
    Zhu, Lei-Lei
    Lu, Zhen-Guo
    Sun, Jun-Die
    Zhao, Jun
    Wang, Hai-Feng
    Xiang, Zuo-Lin
    CANCER IMAGING, 2023, 23 (01)
  • [10] Recommendations and Clinical Validation of Inguinal Clinical Target Volume Delineation in Penile Cancer
    Mittal, Rishi
    Krishnatry, Rahul
    Maitre, Priyamvada
    Murthy, Vedang
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : 741 - 753